.avif)
Allovir Email Format
Biotechnology Research
・
51-200 employees
・
Waltham, MA, USA
AlloVir is a biotechnology company developing novel allogeneic cell therapies to restore natural immunity against life-threatening viral diseases in immunocompromised patients.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@allovir.com
Company Overview
Industry
Biotechnology Research
Founded
2013
Headquarters
Waltham, MA, USA
Revenue
$10M-$25M
FUNDING Stage
Public
Website
Key Executives
Andrew Oxtoby (President and Chief Executive Officer), Brett Hagen (Chief Accounting Officer and Principal Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Allovir?
Allovir uses the firstinitiallast format on allovir.com, so Jane Smith would be jsmith@allovir.com.
What type of therapies did Allovir develop before its merger with Kalaris Therapeutics?
Allovir focused on allogeneic, off-the-shelf, virus-specific T cell therapies designed to restore natural immunity in severely immunocompromised patients, including those who had undergone hematopoietic cell transplants. Its lead program was posoleucel, targeting six clinically significant viral infections.
How can I find and verify an Allovir employee email address for outreach?
Since Allovir uses the firstinitiallast format at allovir.com, you can build a contact's email using their first initial and last name. A tool like Clay can help you verify those addresses and enrich your outreach list with additional contact details.
Where is Allovir headquartered, and what is the combined company now called after the Kalaris merger?
Allovir was headquartered in Waltham, Massachusetts. After its merger with Kalaris Therapeutics closed in early 2025, the combined company now operates under the Kalaris Therapeutics name and trades on Nasdaq under the ticker KLRS.
Who leads Allovir as President and Chief Executive Officer?
Andrew Oxtoby serves as President and Chief Executive Officer of Allovir. He also led the combined company following Allovir's merger with Kalaris Therapeutics, where he had previously served as CEO prior to the merger closing.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating